Meningococcal disease is caused by the bacterium *Neisseria meningitidis*. These bacteria have at least 13 different subtypes (serogroups). Five of these serogroups, A, B, C, Y, and W, cause almost all invasive disease. The relative importance of these five serogroups depends on geographic location and other factors. In the United States almost all meningococcal disease is caused by serogroups B, C, W and Y. Serogroups C, W, and Y account for more than half of reported cases.

How does meningococcal disease spread?
The disease is spread person-to-person through the exchange of respiratory and throat secretions (e.g., by coughing, kissing, sharing eating utensils). Meningococcal bacteria can't live for more than a few minutes outside the body, so the disease is not spread as easily as the common cold or influenza.

How long does it take to show signs of meningococcal disease after being exposed?
The incubation period of meningococcal disease is 3 to 4 days, with a range of 2 to 10 days. Meningococcal bacteria can make a person extremely ill by infecting the blood (septicemia) or by infecting the fluid of the spinal cord and around the brain (meningitis). Because this disease progresses quickly, it is important to be diagnosed and start treatment as soon as possible.

What are the symptoms of meningococcal disease?
The most common symptoms are high fever, chills, tiredness, and a rash. If meningitis is present, the symptoms will also include headache and neck stiffness (which may not be present in infants); seizures may also occur. In overwhelming meningococcal infections, shock, coma, and death can follow within several hours, even with appropriate medical treatment.

How serious is meningococcal disease?
Meningococcal disease caused by any serogroup is very serious. About one out of seven people with meningococcal disease die even with appropriate antibiotic treatment. Of those who recover, up to one out of five suffer from some serious after-effects, such as permanent hearing loss, limb loss, or brain damage.

How is meningococcal disease diagnosed?
The diagnosis is made by taking samples of blood and spinal fluid from a person who is sick. The spinal fluid is obtained by performing a lumbar puncture, where a needle is inserted into the lower back. Any bacteria found in the blood or spinal fluid is grown in a medical laboratory and identified.

Meningococcal disease is rare in the United States, and the symptoms can be mistaken for other illnesses, which unfortunately can lead to delayed diagnosis and treatment.

Can't meningitis be caused by a virus too?
Yes. The word "meningitis" refers to inflammation of the tissues covering the brain and spinal cord. This inflammation can be caused by viruses and fungi, as well as bacteria. Viral meningitis is the most common type; it has no specific treatment but is usually not as serious as meningitis caused by bacteria.

Is there a treatment for meningococcal disease?
Meningococcal disease can be treated with antibiotics. It is important to start treatment early.

How common is meningococcal disease in the United States?
Fewer than 500 cases of meningococcal disease were reported each year since 2010 in the United States. In 2018, a total of 329 cases were reported and 39 died. The disease is most common in children younger than 5 years (particularly children younger than age 1 year), people age 16–21 years, and people age 65 years and older.

What people are at special risk for meningococcal disease?
Risk factors for meningococcal disease include having a recent viral infection, household crowding, and cigarette smoke exposure (direct or second-hand smoke). In addition, certain people are at higher risk than other people their age for meningococcal disease caused by any serogroup. These include people with a damaged or missing spleen, those with complement disorders (an immune system disorder) or who take a complement

CONTINUED ON THE NEXT PAGE
inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris], sutimlimab [Enjaymo]), as well as microbiologists who routinely handle meningococcal isolates.

Certain people are at increased risk for meningococcal serogroups A, C, W, and Y but not serogroup B. These include travelers to regions where meningococcal disease is more common (such as sub-Saharan Africa) and people living with HIV.

**Does meningococcal disease occur in other parts of the world?**

Meningococcal disease occurs throughout the world, but is more common in the area of Africa known as the “meningitis belt” that stretches from Senegal to Ethiopia. Serogroup A was common in sub-Saharan Africa but is now rare thanks to a major vaccination campaign. Serogroups C and W now dominate in the “meningitis belt.”

**Can you get meningitis more than once?**

Yes. Meningitis can be caused by different serogroups of the meningococcal bacterium, by other bacteria such as *Streptococcus* and *Haemophilus*, as well as by viruses and fungi. Being vaccinated against *Neisseria meningitidis* or having had the disease will not protect you against meningitis from other bacteria or viruses.

**If a child is diagnosed with meningococcal disease, can anything be done to protect the other children with whom he has contact?**

People exposed to someone with bacterial meningitis can be protected by being started on a course of antibiotics immediately (ideally within 24 hours of the patient being diagnosed). This is usually recommended for household contacts and children attending the same day care or nursery school. Older children and adults (e.g., who are in the same school or church) aren’t usually considered exposed unless they have had very close contact with the infected person (e.g., kissing or sharing a glass).

In addition to the antibiotic treatment, vaccination may be recommended for people 2 months of age and older if the person’s infection is caused by meningococcus serogroup A, C, Y, or W.

**What meningococcal vaccines are available in the United States?**

Different meningococcal vaccines are available that protect against different serogroups. There are two products (Menveo and MenQuadfi) that protect against serogroups A, C, W, and Y (abbreviated MenACWY). There are two products (Bexsero and Trumenba) that protect against serogroup B (abbreviated MenB). One vaccine (Penbraya), licensed in 2023, combines a MenACWY vaccine with the Trumenba brand of MenB in a single combination vaccine (abbreviated MenABCWY). Protection from all 5 serogroups requires the use of vaccines (either separately or in combination) targeting all 5 serogroups.

**How is this vaccine given?**

MenACWY vaccines are given in a leg muscle of a young child or the deltoid (arm) muscle of an older child or adult. MenB and MenABCWY vaccines are given intramuscularly, typically in the deltoid muscle, or alternatively, in the anterolateral thigh.

**Who should get the meningococcal vaccine?**

Certain groups should be vaccinated against all 5 serotypes (A, C, W, Y, and B). Others are recommended to receive MenACWY only.

**MenACWY** is recommended for these groups:

- All children and teens, ages 11 through 18 years (catch up vaccination of people age 19 through 21 who have not received a dose since turning 16 can be considered)
- People age 2 months and older who have a damaged or missing spleen.
- People age 2 months and older with a complement disorder (an immune system disorder) or who take a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris], sutimlimab [Enjaymo]).
- People who are at risk during an outbreak caused by a vaccine serogroup.
- People with HIV infection.
- People who are or will be a first-year college student living in a residential facility.

---

**Meningococcal Vaccines Available in U.S.**

<table>
<thead>
<tr>
<th>Trade Name (MFR)</th>
<th>Serogroups Included</th>
<th>Year Licensed</th>
<th>Approved Ages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menveo (GSK)</td>
<td>A, C, W, Y</td>
<td>2010</td>
<td>2 months–55 years*</td>
</tr>
<tr>
<td>MenQuadfi (Sanofi)</td>
<td>A, C, W, Y</td>
<td>2020</td>
<td>2 years and older</td>
</tr>
<tr>
<td>Trumenba (Pfizer)</td>
<td>B</td>
<td>2014</td>
<td>10–25 years†</td>
</tr>
<tr>
<td>Bexsero (GSK)</td>
<td>B</td>
<td>2015</td>
<td>10–25 years†</td>
</tr>
<tr>
<td>Penbraya (Pfizer)</td>
<td>A, B, C, W, Y</td>
<td>2023</td>
<td>10–25 years†</td>
</tr>
</tbody>
</table>

* may be given to people age 56 years or older
† may be given to people age 26 years or older

www.immunize.org/catg.d/p4210.pdf / Item #P4210 (1/19/2024)
• People age 2 months and older who reside in or travel to certain countries in sub-Saharan Africa as well as to other countries for which meningococcal vaccine is recommended (e.g., travel to Mecca, Saudi Arabia, for the annual Hajj).
• People working with meningococcus bacteria in laboratories.

**MenB** is recommended for these groups:
• People age 10 years and older who have a damaged or missing spleen.
• People age 10 years and older with a complement disorder (an immune system disorder) or who take a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris], sutimlimab [Enjaymo]).
• People who are at risk due to a meningococcal serogroup B outbreak.
• People working with meningococcus bacteria in laboratories.

MenB vaccines are not routinely recommended for all adolescents or college students. However, CDC recommends that a MenB vaccine series may be administered to individuals age 16 through 23 with a preferred age of vaccination of 16 through 18 years. This shared clinical decision-making recommendation allows the clinician and patient to decide on MenB vaccination based on the risk and benefit for the individual patient.

People age 10 years and older who need MenACWY and MenB vaccination may receive the separate vaccine brands or the Penbraya MenABCWY combination vaccine.

**What information should healthy people age 16 through 23 years and their healthcare provider consider when deciding on the use of MenB vaccine?**

Considerations for shared clinical decision-making for vaccination against meningococcal B disease include:
• MenB disease is serious, with high rates of death and disability.
• MenB disease is rare (between 4 and 21 cases per year since 2018 in people age 16 through 23 years in the United States).
• Risk of MenB disease is higher among college students, especially those who are freshmen, attend a 4-year university, live on campus, or participate in fraternities or sororities.
• MenB vaccines protect against most serogroup B strains.
• MenB vaccines provide short-term protection, with protective antibody levels declining within 1–2 years.

• MenB vaccines may prevent illness but a vaccinated person may still carry the serogroup B bacteria in their nose.

**Should college students be vaccinated against meningococcal disease?**

The MenACWY vaccine is recommended for first-year college students who are or will be living in a residence facility if they have not had a dose of MenACWY vaccine since turning 16 or if it has been at least 5 years since their most recent dose of MenACWY vaccine. Some colleges and universities require incoming freshmen and others to be vaccinated with MenACWY.

With widespread use of MenACWY vaccines, the risk for meningococcal disease among college students is greatest for serogroup B, although serogroup B disease in this group is still rare. College students age 16 through 23 may choose to receive MenB vaccine to reduce their risk of MenB disease. Some colleges require MenB vaccination in addition to MenACWY.

**How many doses of meningococcal vaccine are needed?**

For MenACWY vaccines the number of doses recommended depends on the age when the vaccine is given and the presence of certain medical conditions or risk factors.

For MenACWY vaccines, this includes
• Adolescents at age 11 or 12 years plus a booster dose at age 16 years.
• If vaccinated at age 13–15 years, give booster dose at age 16–18 years.
• For first-year college students who will live in a residential facility, give booster dose if their previous dose was given before age 16 years or if the dose was given at age 16 or older and it has been at least 5 years since the most recent MenACWY dose.
• Adults age 19–21 who did not receive a dose after their 16th birthday may be given a catch-up dose.

More than 1 dose may be needed for people with a damaged or missing spleen, people with HIV infection, and those with a complement disorder (an immune system disorder) or who take a complement inhibitor (e.g., eculizumab [Soliris], ravulizumab [Ultomiris], sutimlimab [Enjaymo]). In addition, vaccinated people who remain at risk should receive a booster dose of MenACWY every 5 years.

**CONTINUED ON THE NEXT PAGE**
The CDC recommends that people not at increased risk of meningococcal B disease (healthy people age 16 through 23 years) may receive a 2-dose series of Bexsero or Trumenba, preferably at age 16 through 18 years.

People ages 10 years and older with risk factors (i.e., anatomic/functional asplenia, persistent complement component deficiency, complement inhibitor use, or who work with meningococcus bacteria in laboratories) should receive either the 2-dose Bexsero series or a 3-dose Trumenba series. They should receive a MenB booster 1 year after completing a MenB primary series, and then boosters every 2–3 years thereafter, for as long as increased risk remains. For people age 10 years and older who are determined by public health officials to be at increased risk during an outbreak, CDC recommends a one-time booster dose if it has been 1 or more years since completion of a MenB primary series. Local public health officials may reduce this interval to 6 months, depending on the outbreak situation.

Because the two brands of MenB vaccine work differently, it is important that all booster doses be the same brand as the primary series. When the Trumenba brand of MenB and MenACWY vaccine is needed at the same visit, the combination MenABCWY vaccine, Penbraya, may be used. Do not use Penbraya if it has been less than 6 months since a previous dose of Penbraya. Penbraya contains the Trumenba brand of MenB: it should not be used in a series with Bexsero.

**How soon after their first MenACWY dose should people who remain at risk for meningococcal disease be vaccinated again?**

The time between the primary (initial) doses(s) of MenACWY and the first booster varies. Children who received their primary MenACWY dose(s) before their seventh birthday should get their first booster 3 years after their primary dose(s) and every 5 years thereafter, as long as they remain at risk.

**What are the side effects of these vaccines?**

Up to about half of people who get MenACWY vaccines have mild side effects, such as redness or pain where the shot was given. These symptoms usually last for one or two days. A small percentage of people who receive the vaccine develop a fever. Severe reactions, such as a serious allergic reaction, are very rare.

The most common side effect of MenB vaccine is pain at the injection site, which is reported by most vaccine recipients. The Vaccine Adverse Event Reporting System (VAERS) and other vaccine safety systems carefully monitor MenACWY and MenB vaccine safety as they do for other U.S.-licensed vaccines.

**How effective is this vaccine?**

Based on antibody studies and comparison with an older meningococcal vaccine, MenACWY is believed to be at least 85% effective.

Because serogroup B meningococcal disease is rare, MenB vaccine efficacy estimates were based on demonstration of an immune response after vaccination. From 63% to 88% of recipients of a full series of MenB vaccine develop a protective level of antibody against representative strains of serogroup B meningococcus.

**Who should not receive meningococcal vaccine?**

These groups should not receive either type of meningococcal vaccine:

- People who have had a serious allergic reaction to a previous dose of either meningococcal vaccine or to one of the vaccine components. The packaging of some meningococcal vaccines may contain latex. Information on the contents of each vaccine is included with each vaccine.
- People who are moderately or severely ill.

**Can a pregnant person get meningococcal vaccine?**

Post-licensure safety data suggest no concerns with the safety of MenACWY during pregnancy. Pregnancy is not a contraindication nor a precaution to MenACWY vaccination. Healthcare personnel should administer this vaccine to high-risk pregnant people. Although experience with MenB vaccines is limited, they have not been shown to be detrimental to a pregnant person or fetus. Pregnancy is a precaution to MenB vaccine. Healthcare personnel can administer this vaccine to high-risk pregnant people.